{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T04:49:42Z","timestamp":1776487782757,"version":"3.51.2"},"reference-count":20,"publisher":"Oxford University Press (OUP)","issue":"Supplement_2","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":16,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,10,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Despite the substantial societal impact of prevalent endocrine diseases like obesity, diabetes, infertility, and thyroid disorders, plus over 440 rare endocrine conditions, it remains unclear whether endocrine science receives adequate research funding to address present and future health challenges.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We analysed the funding for endocrine science under the EU Research Framework Programme Horizon 2020 (2014-2020) using the EU CORDIS database. Through keyword searches and European Science Vocabulary Classification Codes, we identified relevant projects and analysed total funding, distribution across endocrine areas, funding mechanisms (top-down vs bottom-up), and geographical allocation. We also conducted a preliminary analysis of the ongoing Horizon Europe (2021-2027) program.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Horizon 2020 funded 331 endocrine research projects totalling \u20ac615\u2005M, representing 3.9% of biomedical and health research funding. Nearly 70% was allocated to diabetes and obesity, with an additional 17.4% to environmental factors affecting endocrine health, predominantly through top-down funding schemes reflecting European Commission priorities. All other endocrinology areas combined received just 13.6% of endocrine funding, primarily through smaller bottom-up grants. Geographical analysis revealed significant disparities, with EU Widening Countries receiving only 4% of funding. Preliminary Horizon Europe data (\u20ac57.7\u2005M) shows similar distribution patterns and persistent geographical inequities.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>The high prevalence of endocrine disorders warrants greater research funding allocation toward endocrine science. To address this funding gap, the European Society of Endocrinology and the European Society of Paediatric Endocrinology, together with partner societies and individual experts, have created the EndoCompass roadmap project\u2014a research roadmap for better hormone health.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ejendo\/lvaf067","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T09:02:14Z","timestamp":1760691734000},"page":"ii3-ii11","source":"Crossref","is-referenced-by-count":2,"title":["EndoCompass project: the place of endocrinology in European research funding\u2014an analysis of Horizon 2020"],"prefix":"10.1093","volume":"193","author":[{"given":"Sr\u0111an","family":"Pandurevi\u0107","sequence":"first","affiliation":[{"name":"European Society of Endocrinology , Bristol ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yulia","family":"Matskevitch","sequence":"additional","affiliation":[{"name":"EU Funding Consultant , Brussels ,","place":["Belgium"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"De Rijdt","sequence":"additional","affiliation":[{"name":"European Society of Endocrinology , Bristol ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"key":"2025101705020700400_lvaf067-B1","volume-title":"WHO European Regional Obesity Report 2022","author":"Europe WHORO for","year":"2022"},{"key":"2025101705020700400_lvaf067-B2","author":"Cancer IA for R on"},{"key":"2025101705020700400_lvaf067-B3","volume-title":"IDF Diabetes Atlas","author":"Federation","year":"2021","edition":"10th Edition"},{"key":"2025101705020700400_lvaf067-B4","volume-title":"Infertility Prevalence Estimates, 1990-2021","author":"Organization","year":"2023"},{"key":"2025101705020700400_lvaf067-B5","author":"System"},{"issue":"2","key":"2025101705020700400_lvaf067-B6","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.surg.2019.09.010","article-title":"Financial burden of thyroid cancer in the United States: an estimate of economic and psychological hardship among thyroid cancer survivors","volume":"167","author":"Barrows","year":"2020","journal-title":"Surgery"},{"key":"2025101705020700400_lvaf067-B7","author":"European Parliamentary Research Services"},{"key":"2025101705020700400_lvaf067-B8","author":"ESE Focus Areas","year":"2025"},{"key":"2025101705020700400_lvaf067-B9","author":"EURION cluster","year":"2024"},{"key":"2025101705020700400_lvaf067-B10","author":"The Human Exposome Project"},{"key":"2025101705020700400_lvaf067-B11","author":"A cancer plan for Europe","year":"2025"},{"key":"2025101705020700400_lvaf067-B12"},{"key":"2025101705020700400_lvaf067-B13"},{"issue":"3","key":"2025101705020700400_lvaf067-B14","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1210\/jc.2013-2409","article-title":"The incidence and prevalence of thyroid dysfunction in Europe: a meta-analysis","volume":"99","author":"Garmendia Madariaga","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"2025101705020700400_lvaf067-B15","author":"Quaglio"},{"key":"2025101705020700400_lvaf067-B16","doi-asserted-by":"publisher","volume-title":"Accelerate\u2014Research, Technology and Innovation to Boost European Competitiveness","year":"2024","DOI":"10.2777\/9106236"},{"key":"2025101705020700400_lvaf067-B17","doi-asserted-by":"publisher","DOI":"10.48550\/arXiv.2308.07162","article-title":"Evolution of public funding for collaborative health research towards higher level patient-oriented research","author":"Fajardo-Ortiz","journal-title":"preprint"},{"key":"2025101705020700400_lvaf067-B18","author":"Sipido"},{"key":"2025101705020700400_lvaf067-B19","doi-asserted-by":"publisher","DOI":"10.2777\/682623","volume-title":"The Added Value of European Investments in Research and Innovation","author":"European Commission DG for R and I","year":"2024"},{"key":"2025101705020700400_lvaf067-B20","author":"ESE Team"}],"container-title":["European Journal of Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/Supplement_2\/ii3\/64633687\/lvaf067.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ejendo\/article-pdf\/193\/Supplement_2\/ii3\/64633687\/lvaf067.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T09:02:16Z","timestamp":1760691736000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ejendo\/article\/193\/Supplement_2\/ii3\/8281962"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":20,"journal-issue":{"issue":"Supplement_2","published-print":{"date-parts":[[2025,10,17]]}},"URL":"https:\/\/doi.org\/10.1093\/ejendo\/lvaf067","relation":{},"ISSN":["0804-4643","1479-683X"],"issn-type":[{"value":"0804-4643","type":"print"},{"value":"1479-683X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,10]]},"published":{"date-parts":[[2025,10]]}}}